Radius Health, Inc.

NasdaqGM:RDUS Rapport sur les actions

Capitalisation boursière : US$480.8m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Radius Health Croissance future

Future contrôle des critères 4/6

Informations clés

53.5%

Taux de croissance des bénéfices

50.4%

Taux de croissance du BPA

Biotechs croissance des bénéfices28.5%
Taux de croissance des recettes10.1%
Rendement futur des capitaux propresn/a
Couverture par les analystes

Good

Dernière mise à journ/a

Mises à jour récentes de la croissance future

Recent updates

Radius Recycling Stays In The Scrap Pile

Jul 16

Radius Recycling: An Attractive, But Volatile, Play On A Cleaner Future

Jun 03

Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype

Aug 11

Reevaluating Radius Health

Feb 24

Radius Health EPS misses by $0.02, misses on revenue

May 07

When Will Radius Health, Inc. (NASDAQ:RDUS) Become Profitable?

Feb 23
When Will Radius Health, Inc. (NASDAQ:RDUS) Become Profitable?

Revisiting Radius Health

Feb 01

Radius Health acquires global rights to RAD011 in Prader-Willi syndrome

Jan 06

How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?

Jan 01
How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?

Radius Health on-track for record quarterly revenue for TYMLOS-SC

Dec 15

Prévisions de croissance des bénéfices et des revenus

NasdaqGM:RDUS - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/202430036N/AN/A5
12/31/202327212N/AN/A6
12/31/2022232-10N/AN/A3
6/30/2022223-69-28-28N/A
3/31/2022217-73-44-44N/A
12/31/2021230-70-22-22N/A
9/30/2021228-76-52-52N/A
6/30/2021249-60-62-62N/A
3/31/2021247-87-60-60N/A
12/31/2020239-109-74-74N/A
9/30/2020232-113-54-54N/A
6/30/2020200-136-75-75N/A
3/31/2020191-128-81-81N/A
12/31/2019173-133-82-82N/A
9/30/2019152-149-115-115N/A
6/30/2019133-169-137-137N/A
3/31/2019115-203-169-169N/A
12/31/201899-221-205-205N/A
9/30/201872-251-204-204N/A
6/30/201858-259-217-215N/A
3/31/201837-259-235-224N/A
12/31/201722-254-218-207N/A
9/30/201714-236-216-204N/A
6/30/20171-224-192-180N/A
3/31/2017N/A-199-162-159N/A
12/31/2016N/A-183-143-140N/A
9/30/2016N/A-163-133-130N/A
6/30/2016N/A-145-123-121N/A
3/31/2016N/A-125N/A-101N/A
12/31/2015N/A-102N/A-87N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: RDUS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Bénéfices vs marché: RDUS is forecast to become profitable over the next 3 years, which is considered above average market growth.

Croissance élevée des bénéfices: RDUS is expected to become profitable in the next 3 years.

Chiffre d'affaires vs marché: RDUS's revenue (10.1% per year) is forecast to grow faster than the US market (8% per year).

Croissance élevée des revenus: RDUS's revenue (10.1% per year) is forecast to grow slower than 20% per year.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: Insufficient data to determine if RDUS's Return on Equity is forecast to be high in 3 years time


Découvrir les entreprises en croissance